Physician profile
Yanina Kovler
NPI 1124212998
$27,469.79
in general payments reported to CMS, 2019-2025
36 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,071 · 2020: $3,467 · 2021: $7,150 · 2022: $4,820 · 2023: $2,762 · 2024: $2,407 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,337 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,336.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,625.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,198.74 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $5,340.65 | 2019-2024 | Linzess |
| Allergan, INC. | $5,053.70 | 2019-2020 | |
| Amgen INC. | $2,395.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $822.17 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $707.18 | 2019-2025 | Breztri |
| Nestle Healthcare Nutrition INC. | $571.53 | 2020-2023 | |
| Ardelyx, INC. | $469.37 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $463.71 | 2019-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.69 | 2019-2023 | Trulance, Xifaxan |
| Aimmune Therapeutics, INC. | $399.90 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $334.47 | 2019-2024 | |
| Astellas Pharma US INC | $316.13 | 2019-2024 | Veozah, Myrbetriq |
| Corcept Therapeutics | $270.19 | 2024-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $217.04 | 2024 | Fanapt |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $201.46 | 2024-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $152.75 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.93 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $119.85 | 2025 | Cobenfy |
| Amarin Pharma, INC. | $109.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $84.95 | 2024-2025 | Nexletol |
| Pfizer INC. | $84.35 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $82.13 | 2025 | Recorlev, Gvoke Hypopen |
| Vivus LLC | $79.82 | 2020-2025 | Pancreaze |
| Amneal Pharmaceuticals LLC | $51.20 | 2024 | Unithroid |
| Eisai INC. | $50.47 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $49.24 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $42.97 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $41.83 | 2022 | |
| Incyte Corporation | $41.01 | 2022 | |
| Intra-Sana Laboratories | $40.83 | 2023-2024 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Novo Nordisk INC | $22.23 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $21.68 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.80 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.82 | 2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $14.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanina Kovler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.